Funding for Department of Defense Clinical Trial Grant of Lupus
Officials with the U.S. Department of Defense Congressionally Directed Peer Review Medical Research Program have announced two new research grants that advance efforts to help solve the cruel mystery of lupus by supporting clinical and basic research. Immunomedics, Inc. a New Jersey based biopharmaceutical company will receive a three-year grant of more than $1.6 million to evaluate milatuzumab as a potential treatment for patients with lupus. SRI International, a nonprofit research institute located in Menlo Park, California, will receive a grant of nearly $250,000 for research to evaluate ways to prevent B cells from producing “self-antibodies” as one possible approach to stopping lupus.
These two grants bring the total DOD support for lupus research to $14 million since 2005, when the Lupus Foundation of America successfully advocated to have lupus included among the diseases eligible for funding through the Congressionally Directed Peer Review Medical Research Program. The program to date has awarded 16 grants for lupus research.